Lancaster-based Simulations Plus entered a funded collaboration with an unnamed large pharmaceutical company that will enhance one of the company’s simulation software programs.
News Category Global Banking & Finance Reviews
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to add novel mechanisms for oral peptide formulations within the top-rated GastroPlus Advanced Compartmental Absorption and Transit (ACAT„¢) mechanistic model. Our partner, a frequent user of the GastroPlus platform across multiple research sites worldwide, has a growing portion of their development pipeline focused on therapeutic peptides and proteins, said Dr. Viera Lukacova, chief scientist at Simul